Mathurin Fumery

39PUBLICATIONS
84CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Preventative health careInnate immunityDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (39)

|Mar 25, 2026
Efficacy and Safety of Second-Line Advanced Therapy After Vedolizumab in Ulcerative Colitis: A Multicenter Cohort Study From the GETAID.

Louis Calméjane, Catherine Reenaers, Claire Gay

|Mar 06, 2026
Subcutaneous infliximab in inflammatory bowel disease: bridging the gap between theory and practice.

Lucine Vuitton, Mathurin Fumery, Lucile Foulley

|Dec 02, 2025
Intestinal Ultrasound Transmural Healing Was Associated With Improved Long-Term Outcomes Among Patients With Endoscopic Remission: Results of a Prospective Study.

Clara Yzet, Amélie Plancke, Franck Brazier

|Aug 28, 2025
Subcutaneous Infliximab for Perianal Crohn's Disease: The BioLap-Rem Multicenter Study From the GETAID.

Marie André, Julien Kirchgesner, David Laharie

|Aug 25, 2025
Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study.

Xavier Roblin, Sophie Vieujean, Stéphane Nancey

|Jul 12, 2025
Efficacy and Safety of Infliximab and Vedolizumab Maintenance Therapy in Patients with Crohn's Disease and Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Bruce E Sands, Laurent Peyrin-Biroulet, Stefan Schreiber

Pageof 7

Frequent Collaborators

10 joint publications

Laurent Peyrin-Biroulet

9 joint publications

Anthony Buisson

9 joint publications

David Laharie

8 joint publications

Guillaume Bouguen